Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical CO Ltd (TAK)

Takeda Pharmaceutical CO Ltd (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,159,356
  • Shares Outstanding, K 3,152,750
  • Annual Sales, $ 30,279 M
  • Annual Income, $ 407,020 K
  • 60-Month Beta 1.01
  • Price/Sales 1.81
  • Price/Cash Flow 5.01
  • Price/Book 1.25
Trade TAK with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.53
  • Growth Rate Est. (year over year) +188,390.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.25 +5.10%
on 01/21/21
18.58 -2.42%
on 01/11/21
-0.33 (-1.79%)
since 12/22/20
3-Month
15.30 +18.47%
on 10/30/20
19.10 -5.08%
on 12/14/20
+1.49 (+8.95%)
since 10/22/20
52-Week
12.43 +45.86%
on 03/18/20
20.42 -11.21%
on 02/07/20
-1.79 (-8.99%)
since 01/22/20

Most Recent Stories

More News
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda

Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Moderna's...

TKPYY : 16.5900 (-0.90%)
MRNA : 131.02 (-1.47%)
TAK : 18.13 (+4.80%)
Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan Healthcare Conference

--a^' Wave 1 Pipeline Portfolio Includes 12 New Molecular Entities Targeted for Launch by FY2024 Representing Best-in-Class/First-in-Class Therapies with Significant Market Potential

JPM : 133.79 (-0.77%)
TAK : 18.13 (+4.80%)
Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m....

JPM : 133.79 (-0.77%)
TKPYY : 16.5900 (-0.90%)
TAK : 18.13 (+4.80%)
Takeda Completes Sale of Select Non-Core Assets to Cheplapharm

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a...

TKPYY : 16.5900 (-0.90%)
TAK : 18.13 (+4.80%)
Bristol Myers' (BMY) Application for UC Drug Validated by EMA

Bristol Myers' (BMY) MAA for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis gets validated by EMA.

PFE : 36.55 (+0.19%)
BMY : 64.56 (+0.59%)
HALO : 49.50 (+4.21%)
TAK : 18.13 (+4.80%)
Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix

Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.

PFE : 36.55 (+0.19%)
ABBV : 110.86 (-0.36%)
MYOV : 20.86 (+0.97%)
TAK : 18.13 (+4.80%)
Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma

Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.

IRWD : 10.34 (+0.78%)
KPTI : 15.09 (+0.20%)
BLCM : 4.17 (-3.25%)
TAK : 18.13 (+4.80%)
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

--a^' Fast tracks innovative medicines to patients in China in key business areas

TKPYY : 16.5900 (-0.90%)
TAK : 18.13 (+4.80%)
Prime Therapeutics and Takeda agree to outcomes-based arrangement for Hemophilia A treatment ADVATE® [Antihemophilic Factor (Recombinant)]

, /PRNewswire/ -- In an effort to help assess the value of hemophilia A treatments relative to total health care costs and emergency department visits, Prime Therapeutics LLC (Prime) has finalized an...

TKPYY : 16.5900 (-0.90%)
TAK : 18.13 (+4.80%)
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda's TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for review the company's New Drug Application...

TKPYY : 16.5900 (-0.90%)
TAK : 18.13 (+4.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 19.33
2nd Resistance Point 18.76
1st Resistance Point 18.44
Last Price 18.13
1st Support Level 17.55
2nd Support Level 16.98
3rd Support Level 16.66

See More

52-Week High 20.42
Last Price 18.13
Fibonacci 61.8% 17.37
Fibonacci 50% 16.42
Fibonacci 38.2% 15.48
52-Week Low 12.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar